BioStock: Medivir's CEO comments on the latest developments

As Medivir reports its fourth quarter, the company’s focus is on the further improved clinical efficacy of fostrox in combination with Lenvima in liver cancer. After recently having strengthened the cash position by more than 140 million SEK, now the aim is to accelerate the initiation of a pivotal phase IIb study and apply for accelerated approval from the FDA. BioStock reached out to CEO Jens Lindberg for a comment.

Read the full interview with Jens Lindberg at biostock.se:

https://www.biostock.se/en/2024/02/medivirs-ceo-comments-on-the-latest-developments/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/